Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Mr. Patrik S. Florencio Esq.

Global Chief Compliance & Risk Officer

Ms. Diana  Moore

Head of Global Corporate Communications

Ms. Ellen S. Rosenberg

Chief Legal Officer & Corporate Secretary

Andrew  Faughnan

Senior Director of Investor Relations

Dr. Jeffrey P. Castelli

Chief Development Officer

Dr. Jill  Weimer Ph.D.

Chief Science Officer

Mr. Bradley L. Campbell M.B.A.

Chief Executive Officer, President & Director

Mr. David M. Clark

Chief People Officer

Mr. Simon Nicolas Reade Harford

Chief Financial Officer

Ms. Samantha  Prout

Chief Accounting Officer & Controller

Биотехнологии

Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. Структура на управлението

Информация за управлението